3
2
1

Professor Wang Xinyu's team from Wuhan University of Technology visited Shandong Yinfeng Life Science Research Institute for investigation and investigation

Release time:

2023-08-05

On the afternoon of August 5th, Professor Wang Xinyu, researcher of the State Key Laboratory of New Materials Composite Technology, chief professor of the discipline, director of Hubei Biomaterials Engineering Technology Research Center, Xiao Shengqiang, researcher of the State Key Laboratory of New Materials Composite Technology of Wuhan University of Technology, Yan Lesan, professor of the Institute of New Materials of Wuhan University of Technology, and Dr. Li Binbin visited Yinfeng Life Science Research Institute for investigation and investigation.

11

The team of professors from Wuhan University of Technology visited cryogenic companies, gene companies, cell therapy companies, Shandong Provincial Cord Blood Bank and Academy of Biological Sciences to learn about the industrial development of enterprises and the research and development of scientific research projects. Mr. Quan Quan, President of Yinfeng Life Science Research Institute, Dr. Xie Sitan, Senior Manager of R&D Department of Yinfeng Biological Group, Zhang Zhizhi, Director of Yinfeng Life Science Research Institute, and Cheng Long, R&D Engineer of Yinfeng Cryogenic Medical Technology Co., Ltd., participated in the symposium.

11

At the meeting, Professor Wang Xinyu of the new materials team introduced his scientific research and productization achievements. The Institute of New Materials of Wuhan University of Technology is the leading biomedical materials R&D and productization team in China, with outstanding achievements and rich experience in the research and development of medical device products in different directions such as oral cavity, skin, joints and bones, especially in oral and joint materials, and the relevant products have the characteristics of low immunogenicity, stability and durability, and have good results in follow-up patient follow-up records.

11

Tissue engineering scaffold materials refer to materials that can be combined with living cells and implanted into different tissues of organisms, and have functions according to specific replacement tissues, including: bone, cartilage, blood vessels, nerves, skin and artificial organs, such as liver, spleen, kidney, bladder, etc. The new materials team is currently committed to the development of materials with vitality, so that the materials implanted in the body can not only replace the original tissue, but also promote tissue regeneration.

Stem cells are a type of cells with unlimited or immortal self-renewal ability, which can produce at least one type of highly differentiated progeny cells, and use stem cells to differentiate under certain conditions to form any type of tissues and organs, and realize non-rejection transplantation of tissues and organs. The two sides exchanged views on the development prospects and cooperation models of biomaterial products.

The Academy of Biological Sciences is committed to the research and development of cutting-edge technologies in the fields of cell medicine, immunology, cryogenic medicine, genetic testing and regenerative medicine, with the mission of "dedicating medical science and technology to ensure human health", continuing to "be honest, working seriously, relaxed, and pioneering and enterprising", and contribute core technical strength to "cutting-edge technology exploration".

Latest developments

【The YinFeng Life Continuation Project Debuts at the 2026 Annual Meeting of the Chinese Medical Association's Medical Ethics Branch—Ethics Leading Biotech Toward Benevolent Innovation】

The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.

Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross

Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.

Yinfeng Life Science Research Institute, in Collaboration with University of Science and Technology of China, Develops CryoSIM Platform, Published in Top Analytical Chemistry Journal Revolutionizing Oocyte Membrane Permeability Analysis Technology

The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).

World’s First Achievement Highlights Brand Leadership

In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.

Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference

Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.